Patients with recurrent and/or metastatic ( R/M ) head and neck squamous cell carcinoma ( HNSCC ) receiving platinum-based chemotherapy as their first-line treatment have a dismal prognosis , with a median overall survival ( OS ) of ~ 7 months .